Gene Expression of AAV-ITR Mini Vector in Mice vivo

doi:10.13560/j.cnki.biotech.bull.1985.2016.05.033

Abstract

Abstract: In order to compare the expression difference between AAV-ITR expression mini vector and its monomers in different parts of mice，the same copy number of AAV-ITR mini vector and pUC57-minivector-EGFP were separately transferred into the brain of mice. In addition，the same copy number of monomers of AAV-ITR mini vector and pUC57-minivector-EGFP were transferred into mouse skeletal muscle，and the number of residual molecules were compared in the different tissues at different periods. Analysis by florescence quantitative PCR，microscope observation，average optical density，and gray value showed that monomers of AAV-ITR mini vector in the same copy number had higher transfection efficiency and more stable than AAV-ITR mini vector and pUC57-minivector-EGFP. The comprehensive results suggest that the monomers of AAV-ITR mini vector present the feature of efficient，secure and stable expression，which may be expected to become a novel，secure，reliable，stable，and efficient vector in gene therapy.

Key words: gene therapy, gene expression mini vector, adeno-associated virus（AAV）, RT-PCR, skeletal muscle section

LI Tai-ming,XU Qi-lin,PAN Jun-jie,LIU Xiao-mei,ZHANG Chun. Gene Expression of AAV-ITR Mini Vector in Mice vivo[J]. Biotechnology Bulletin, 2016, 32(5): 246-254.

References

[1]Seow YQ, Wood MJ. Biological gene delivery vehicles：beyond viral vectors[J]. Molecular therapy, 2009, 17（5）：767-777.
[2]郭勇, 曾庆平. 基因治疗药物的研究进展[J]. 药物生物技术, 1996（3）：181-186.
[3]Marshall E. Gene therapy death prompts review of adenovirus vector. [J]. Science, 1999, 286（5448）：2244-2245.
[4]Chen ZY, He CY, Meuse L, et al. Silencing of episomal transgene expression by plasmid bacterial DNA elements in vivo[J]. Gene Therapy, 2004, 11（10）：856-864.
[5] Pang AS. Production of antibodies against Bacillus thuringiensis delta-endotoxin by injecting its plasmids. [J]. Biochem Biophys Res Commun, 1994, 202（3）：1227-1234.
[6]Bartlett JS. Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors[J]. J Virol, 2000, 74（6）：2777-2785.
[7]Sanlioglu S. Endocytosis and nuclear trafficking of adeno-associated virus type 2 are controlled by rac1 and phosphatidylinositol-3 kinase activation[J]. J Virol, 2000, 74（19）：9184-9196.
[8]Akache. A two-hybrid screen identifies cathepsins B and L as uncoating factors for adeno-associated virus 2 and 8[J]. Mol Ther, 2007, 15（2）：330-339.
[9]Zaiss AK. Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors[J]. J Virol, 2002, 76（9）：4580-4590.
[10]Weindler FW, Heilbronn R. A subset of herpes simplex virus replication genes provides helper functions for productive adeno-associated virus replication[J]. J Virol, 1991, 65（5）：2476-2483.
[11]Summerford. AlphaVbeta5 integrin：a co-receptor for adeno-associated virus type 2 infection[J]. Nat Med, 1999, 5（1）：78-82.
[12]Qing K. Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2[J]. Nat Med, 1999, 5（1）：71-77.
[13]Bakowska JC, Di Maria MV, Camp SM, et al. Targeted transgene integration into transgenic mouse fibroblasts carrying the full-length human AAVS1 locus mediated by HSV/AAV rep（+）hybrid amplicon vector[J]. Gene Ther, 2003, 10（19）：1691-1702.
[14]Huttner NA, Girod A, Schnittqer S, et al. Analysis of site-specific transgene integration following cotransduction with recombinant adeno-associated virus and a rep encodingplasmid[J]. J Gene Med, 2003, 5（2）：120-129.
[15]Manno CS. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B[J]. Blood, 2003, 101（8）：2963-2972.
[16]Maguire AM, High KA, Auricchio A, et al. Safety and efficacy of gene transfer for Leber’s congenital amaurosis[J]. N Engl J Med, 2008, 358（21）：2240-2248.
[17]李泰明, 潘俊杰, 祁静, 等. 昆虫细胞制备 AAV-ITR 基因表达微载体[J]. 生物工程学报, DOI：10. 13345/j. cjb. 140485.
[18]Alberts B. The breakthroughs of 2009. [J]. Science, 2009, 326（5960）：1589.
[19]Yla-Herttuala S. Endgame：glybera finally recommended for approval as the first gene therapy drug in the European union[J]. Mol Ther, 2012, 20（10）：1831-1832.
[20]Miller N. Glybera and the future of gene therapy in the European Union[J]. Nat Rev Drug Discov, 2012, 11（5）：419.
[21] Henckaerts E, Linden RM. Adeno-associated virus：a key to the human genome? [J]. Future Virol, 2010, 5（5）：555-574.
[22] Coura Rdos S, Nardi NB, The state of the art of adeno-associated virus-based vectors in gene therapy[J]. Virol J, 2007, 4：99.
[23] Grieger JC, Samulski RJ. Adeno-associated virus as a gene therapy vector：vector development, production and clinical applications[J]. Adv Biochem Eng Biotechnol, 2005, 99：119-145.
[24] Kobelt D, Schleef M, Schmeer M, et al. Performance of high quality minicircle DNA for in vitro and in vivo gene transfer[J]. Mol Biotechnol, 2013, 53（1）：80-89.
[25] Mayrhofer P, Iro M. Gene Vaccines[M]. Thalhamer J, Weiss R, Scheiblhofer S, Editors. Springer Vienna, 2012：297-310.
[26] Maniar LEG, Maniar JM, Chen ZY, et al. Minicircle DNA vectors achieve sustained expression reflected by active chromatin and transcriptional level[J]. Mol Ther, 2013, 21（1）：131-138.
[27] Mayrhofer P, Schleef M, Jechlinger W. Gene Therapy of Cancer[M]. Methods in Molecular BiologyTM, 2009：87-104.
[28] Duan D, Yan Z, Yue Y, et al. Structural analysis of adeno-associated virus transduction circular intermediates[J]. Virology, 1999, 261（1）：8-14.
[29]Cervelli T, Backovic A, Galli A. Formation of AAV single stranded DNA genome from a circular plasmid in Saccharomyces cerevisiae[J]. PLoS One, 2011, 6（8）：e23474.
[30]Li L, Dimitriadis EK, Yang Y, et al. Production and characterization of novel recombinant adeno-associated virus replicative-form genomes：a eukaryotic source of DNA for gene transfer[J]. PLoS One, 2013, 8（8）：e69879.